Viewing Study NCT06383767


Ignite Creation Date: 2025-12-25 @ 12:35 AM
Ignite Modification Date: 2026-01-04 @ 4:55 PM
Study NCT ID: NCT06383767
Status: RECRUITING
Last Update Posted: 2025-06-19
First Post: 2024-04-22
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer
Sponsor: Qilu Pharmaceutical Co., Ltd.
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module